Glutaminergic Agents for Cocaine Abuse - 5

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000280

Purpose

The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Nimodipine	Phase I

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Glutaminergic Agents for Cocaine Abuse

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Nimodipine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Cocaine effects

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000280

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

Study ID Numbers:	NIDA-09250-5, P50-09250-5
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000280 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Disorders of Environmental Origin
Calcium Channel Blockers
Cardiovascular Agents
Antihypertensive Agents

Pharmacologic Actions
Membrane Transport Modulators
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Nimodipine

ClinicalTrials.gov processed this record on November 27, 2009